Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Etrumadenant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A known ✓ | P29274 | 20/20 | 1.00 |
| ▸ | ADORA2B known ✓ | P29275 | 17/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etrumadenant SCHEMBL29560949 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL20401465 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29393659 | 1.00 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| Etrumadenant SCHEMBL29653560 | 0.94 | ADORA2A (0.89) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417111 | 0.93 | ADORA2A (0.87) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401123 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20436497 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401417 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401229 | 0.89 | ADORA2A (0.80) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20417122 | 0.89 | ADORA2A (0.79) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4271384-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | Incyte Corporation (US) | 2023-11-08 | — | — | EP | claimed |
| EP-4084870-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | Incyte Corporation (US) | 2022-11-09 | — | — | EP | claimed |
| WO-2022147092-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | INCYTE CORPORATION (US) | 2022-07-07 | — | — | WO | claimed |
| US-20250161313-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | disclosed |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (FR) | 2025-05-22 | — | — | US | disclosed |
| EP-4489760-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2025-01-15 | — | — | EP | disclosed |
| EP-4489759-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) | 2025-01-15 | — | — | EP | disclosed |
| US-20240376081-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-11-14 | — | — | US | disclosed |
| EP-4447962-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2024-10-23 | — | — | EP | disclosed |
| EP-4403553-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2024-07-24 | — | — | EP | disclosed |
| CN-118373808-A | Substituted pyrimidine or pyridine amine derivatives, compositions thereof and pharmaceutical use thereof | 上海海雁医药科技有限公司 | 2024-07-23 | — | — | CN | disclosed |
| WO-2023213761-A1 | ADENOSINE 2A RECEPTOR MODULATORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITE DE GENEVE (CH) | 2023-11-09 | — | — | WO | disclosed |
| EP-4271384-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | Incyte Corporation (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2023170103-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023170099-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2023-09-14 | — | — | WO | disclosed |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2023-05-11 | — | — | US | disclosed |
| WO-2023040863-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | 上海海雁医药科技有限公司 | 2023-03-23 | — | — | WO | disclosed |
| EP-4122927-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. (CN) | 2023-01-25 | — | — | EP | disclosed |
| EP-4084870-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | Incyte Corporation (US) | 2022-11-09 | — | — | EP | disclosed |
| WO-2022147092-A1 | COMBINATION THERAPY COMPRISING A2A/A2B INHIBITORS, PD-1/PD-L1 INHIBITORS, AND ANTI-CD73 ANTIBODIES | INCYTE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250161313-A1 | A METHOD FOR THE TREATMENT OF NEUROPATHY | ADORA2A, P2RX2, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA1 12/4885 |
| US-20230145793-A1 | SUBSTITUTED PYRIMIDINE OR PYRIDINE AMINE DERIVATIVE, COMPOSITION THEREOF, AND MEDICAL USE THEREOF | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 4/4885 |
| US-20250161312-A1 | A METHOD FOR THE TREATMENT OF CHEMOTHERAPEUTIC DRUG-INDUCED NEPHROTOXICITY | ADORA2A, ADORA3, ADORA2B | ADORA2A 1/4885ADORA2B 3/4885ADORA1 5/4885 |
| US-20240376081-A1 | POLYMORPH AND APPLICATION OF PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | ADORA2B, ADORA2A, ADORA3 | ADORA2A 2/4885ADORA2B 1/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.